INSM Insmed Inc.

24.29
-0.66  -3%
Previous Close 24.95
Open 24.76
Price To Book 8.35
Market Cap 2,454,378,872
Shares 101,044,828
Volume 1,020,255
Short Ratio
Av. Daily Volume 1,321,302
Stock charts supplied by TradingView

NewsSee all news

  1. Insmed to Present at Two June Conferences

    BRIDGEWATER, N.J., May 26, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  2. Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

    BRIDGEWATER, N.J., May 20, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  3. Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM) announced today the closing of the previously announced public offering of 11,155,000 shares of its common stock, including 1,455,000

  4. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  5. Insmed Announces Pricing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 5, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 2H 2020.
Brensocatib (INS1007)
Bronchiectasis
Phase 2 ready.
INS1009
Pulmonary arterial hypertension (PAH)
Phase 3 Euro data released 1 July 2013. Met endpoint but slighly inferior data to competition
ARIKAYCE
Cystic fibrosis
FDA Approval announced September 28, 2018.
ARIKAYCE
Nontuberculous mycobacterial (NTM) lung disease

Latest News

  1. Insmed to Present at Two June Conferences

    BRIDGEWATER, N.J., May 26, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  2. Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

    BRIDGEWATER, N.J., May 20, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  3. Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM) announced today the closing of the previously announced public offering of 11,155,000 shares of its common stock, including 1,455,000

  4. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  5. Insmed Announces Pricing of Public Offering of Common Stock

    BRIDGEWATER, N.J., May 5, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public

  6. Insmed Announces Proposed Public Offering of Common Stock

    BRIDGEWATER, N.J., May 4, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed

  7. Insmed Reports First Quarter 2020 Financial Results and Provides Business Update

    BRIDGEWATER, N.J., April 30, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported

  8. Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial

    BRIDGEWATER, N.J., April 23, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  9. Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020

    BRIDGEWATER, N.J., April 20, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that

  10. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., April 3, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  11. Insmed Appoints Carol A. Schafer to its Board of Directors

    BRIDGEWATER, N.J., April 2, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  12. Insmed Provides Business Update

    BRIDGEWATER, N.J., March 16, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a

  13. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 5, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  14. Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease

    BRIDGEWATER, N.J., March 4, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  15. Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

    BRIDGEWATER, N.J., Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  16. Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Feb. 25, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported

  17. Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    BRIDGEWATER, N.J., Feb. 19, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  18. Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020

    BRIDGEWATER, N.J., Feb. 10, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  19. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Feb. 5, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  20. Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis

    BRIDGEWATER, N.J., Feb. 3, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  21. Insmed Appoints Sara Bonstein as Chief Financial Officer

    BRIDGEWATER, N.J., Jan. 30, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  22. Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference

    BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  23. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Jan. 3, 2020 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  24. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Dec. 3, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  25. Insmed to Present at Two December Conferences

    BRIDGEWATER, N.J., Nov. 26, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  26. Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer

    BRIDGEWATER, N.J., Nov. 14, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  27. Insmed to Present at Two November Conferences

    BRIDGEWATER, N.J., Nov. 5, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  28. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced

  29. Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported

  30. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  31. Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Sept. 5, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the

  32. Insmed to Present at Two September Conferences

    BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced